Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 8068

Next Previous
Drug Profile

SHR 8068

Alternative Names: SHR-8068

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Biliary cancer; Liver cancer; Non-small cell lung cancer
  • Phase II Colorectal cancer; Gastric cancer; Oesophageal cancer; Solid tumours
  • Phase I/II Renal cancer; Urogenital cancer

Most Recent Events

  • 15 Jul 2026 Suzhou Suncadia Biopharmaceuticals plans a phase II trial for Non-small cell lung cancer (Combination therapy) in China in August 2026 (Parenteral, Injection) (NCT07704645)
  • 09 Jul 2026 Suzhou Suncadia Biopharmaceuticals plans phase III trial in Liver Cancer (Combination therapy) in China in July 2026 (IV, Infusion) (NCT07691762)
  • 02 Jul 2026 Suzhou Suncadia Biopharmaceuticals plans a phase II trial for Liver cancer in China (Parenteral, Injection) (NCT07682272)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top